Research in progress: Medical Research Council United Kingdom Refractory Asthma Stratification Programme (RASP-UK)

Liam G Heaney¹, Ratko Djukanovic², Ashley Woodcock³, Samantha Walker⁴, John G Matthews⁵, Ian D Pavord⁶, Peter Bradding⁷, Robert Niven³, Chris E Brightling⁷, Rekha Chaudhuri⁸, Joseph R Arron⁵, David F Choy⁵, Douglas Cowan⁸, Adel Mansur⁹, Andrew Menzies-Gow¹⁰, Ian Adcock¹¹, Kian F Chung¹¹, Chris Corrigan¹², Peter Coyle¹, Timothy Harrison¹³, Sebastian Johnston¹¹, Peter Howarth², James Lordan¹⁴, Ian Sabroe¹⁵, Jeannette Bigler¹⁶, Dirk Smith¹⁶, Matthew Catley¹⁷, Richard May¹⁷, Lisa Pierre¹⁸, Chris Stevenson¹⁸, Glenn Crater¹⁹, Frank Keane²⁰, Richard W Costello²¹, Val Hudson²², David Supple²², Tim Hardman²³

Affiliations

¹ Centre of Infection and Immunity, The Queens's University of Belfast, Belfast, UK.
² Academic Unit of Clinical and Experimental Sciences, University of Southampton, Southampton, UK.
³ Institute of Inflammation and Repair, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.
⁴ Asthma UK, London, UK Genentech Inc., South San Francisco, California, USA.
⁵ Genentech Inc., South San Francisco, California, USA.
⁶ Nuffield Department of Medicine, The University of Oxford, Oxford, UK.
⁷ Department of Infection, Immunity and Inflammation, Institute for Lung Health, University of Leicester, Leicester, UK.
⁸ Greater Glasgow Health Board, Glasgow, UK.
⁹ Heart of England NHS Foundation Trust, Birmingham, UK.
¹⁰ Royal Brompton & Harefield NHS Foundation Trust, London, UK.
¹¹ Imperial College of Science, Technology and Medicine, London, UK.
¹² Kings College London, London, UK.
¹³ University of Nottingham, Nottingham, UK.
¹⁴ The Newcastle upon Tyne NHS Foundation Trust, Newcastle upon Tyne, UK.
¹⁵ School of Medicine and Biomedical Sciences, University of Sheffield, Sheffield, UK.
¹⁶ Amgen Inc., Thousand Oaks, California, USA.
¹⁷ Astra Zeneca, London, UK.
¹⁸ Jannsen Research & Development LLC, London, UK.
¹⁹ Aerocrine AB, Solna, Sweden.
²⁰ Vitalograph Inc, Ennis, Ireland.
²¹ Department of Medicine, Royal College of Surgeons Ireland, Dublin, Ireland.
²² Public and Patient Representative, London, UK.
²³ Niche Science & Technology, Richmond, UK.

PMID: 26205878
PMCID: PMC4752622
DOI: 10.1136/thoraxjnl-2015-207326

Review

Research in progress: Medical Research Council United Kingdom Refractory Asthma Stratification Programme (RASP-UK)

Liam G Heaney et al. Thorax. 2016 Feb.

. 2016 Feb;71(2):187-9.

doi: 10.1136/thoraxjnl-2015-207326. Epub 2015 Jul 23.

Authors

Affiliations

¹ Centre of Infection and Immunity, The Queens's University of Belfast, Belfast, UK.
² Academic Unit of Clinical and Experimental Sciences, University of Southampton, Southampton, UK.
³ Institute of Inflammation and Repair, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.
⁴ Asthma UK, London, UK Genentech Inc., South San Francisco, California, USA.
⁵ Genentech Inc., South San Francisco, California, USA.
⁶ Nuffield Department of Medicine, The University of Oxford, Oxford, UK.
⁷ Department of Infection, Immunity and Inflammation, Institute for Lung Health, University of Leicester, Leicester, UK.
⁸ Greater Glasgow Health Board, Glasgow, UK.
⁹ Heart of England NHS Foundation Trust, Birmingham, UK.
¹⁰ Royal Brompton & Harefield NHS Foundation Trust, London, UK.
¹¹ Imperial College of Science, Technology and Medicine, London, UK.
¹² Kings College London, London, UK.
¹³ University of Nottingham, Nottingham, UK.
¹⁴ The Newcastle upon Tyne NHS Foundation Trust, Newcastle upon Tyne, UK.
¹⁵ School of Medicine and Biomedical Sciences, University of Sheffield, Sheffield, UK.
¹⁶ Amgen Inc., Thousand Oaks, California, USA.
¹⁷ Astra Zeneca, London, UK.
¹⁸ Jannsen Research & Development LLC, London, UK.
¹⁹ Aerocrine AB, Solna, Sweden.
²⁰ Vitalograph Inc, Ennis, Ireland.
²¹ Department of Medicine, Royal College of Surgeons Ireland, Dublin, Ireland.
²² Public and Patient Representative, London, UK.
²³ Niche Science & Technology, Richmond, UK.

PMID: 26205878
PMCID: PMC4752622
DOI: 10.1136/thoraxjnl-2015-207326

Abstract

The UK Refractory Asthma Stratification Programme (RASP-UK) will explore novel biomarker stratification strategies in severe asthma to improve clinical management and accelerate development of new therapies. Prior asthma mechanistic studies have not stratified on inflammatory phenotype and the understanding of pathophysiological mechanisms in asthma without Type 2 cytokine inflammation is limited. RASP-UK will objectively assess adherence to corticosteroids (CS) and examine a novel composite biomarker strategy to optimise CS dose; this will also address what proportion of patients with severe asthma have persistent symptoms without eosinophilic airways inflammation after progressive CS withdrawal. There will be interactive partnership with the pharmaceutical industry to facilitate access to stratified populations for novel therapeutic studies.

Keywords: Asthma Mechanisms.

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

PubMed Disclaimer

Figures

**Figure 1**
Flow diagram for the RASP-UK Clinical Stratification Programme. ATS, American Thoracic Society; ERS, European Respiratory Society; FeNO, fractional exhaled nitric oxide; FP, Fluticasone Propionate; RASP-UK, UK Refractory Asthma Stratification Programme.

See this image and copyright information in PMC

References

1. Arron JR, Choy DF, Scheerens H, et al. . Non-invasive biomarkers that predict treatment benefit from biologic therapies in asthma. Ann Am Thorac Soc 2013;10(Suppl):S206–13. 10.1513/AnnalsATS.201303-047AW - DOI - PubMed
1. Heaney LG, Horne R. Non-adherence in difficult asthma; time to take it seriously. Thorax 2012;67:268–70. 10.1136/thoraxjnl-2011-200257 - DOI - PubMed
1. Kupczyk M, ten Brinke A, Sterk PJ, et al. . Frequent exacerbators—a distinct phenotype of severe asthma. Clin Exp Allergy 2014;44:212–21. 10.1111/cea.12179 - DOI - PubMed
1. Green RH, Brightling CE, McKenna S, et al. . Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002;360:1715–21. 10.1016/S0140-6736(02)11679-5 - DOI - PubMed
1. Petsky HL, Cates CJ, Lasserson TJ, et al. . A systematic review and meta-analysis: tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils). Thorax 2012;67:199–208. 10.1136/thx.2010.135574 - DOI - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Consumer Health Information
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Research in progress: Medical Research Council United Kingdom Refractory Asthma Stratification Programme (RASP-UK)

Affiliations

Research in progress: Medical Research Council United Kingdom Refractory Asthma Stratification Programme (RASP-UK)

Authors

Affiliations

Abstract

Figures

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Medical